Democrats pressed the White House for answers this week after it denied a STAT News report suggesting President Donald Trump may have received access to an experimental weight loss drug under the Food and Drug Administration’s “compassionate use” program, which is often reserved for patients with life-threatening conditions.
Key Facts
Sen. Maggie Hassan, D-N.H., said in a Wednesday letter addressed to Health and Human Services Secretary Robert F. Kennedy Jr. that she was “deeply concerned” by reports that suggested he “may be bending the rules of a federal program, and exerting improper political pressure, in order to provide a well-connected individual
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.